Hyaluronic acid, a natural compound found in the skin, connective tissues, and joints, is vital for maintaining skin hydration, volume, and elasticity.
The use of hyaluronic acid in beauty products and treatments is widespread, providing effective methods for enhancing natural beauty. It is crucial for medical professionals to be aware of potential side effects and how to prevent and manage them.
Potential Negative Effects of HA Injections
Common and mild side effects may include:
- Swelling, bruising, redness, pain, discomfort, and itching at the injection site;
Less common reactions might involve:
- Development of small lumps or infection;
Rare and severe side effects could include:
- Allergic reactions, vascular complications, or small nodules;
While oral intake of HA has no adverse effects, caution is advised for patients with liver issues due to potential risks of thrombosis from increased HA levels. It is important for patients to discuss these potential negative effects with their healthcare provider before undergoing HA injections.
Recognizing and Managing Early Signs of HA Reactions
Early indications of adverse reactions to hyaluronic acid may include swelling, bruising, redness, discomfort, lumps, or allergic symptoms that require immediate medical attention.
Addressing HA Side Effects: A Healthcare Professional’s Approach
Healthcare providers can identify and manage early signs of HA side effects through patient evaluation, appropriate treatment administration, and recommendations for at-home care.
Taking Preventative Measures against HA Side Effects
To prevent adverse reactions to hyaluronic acid, it is important for patients to follow these guidelines:
- Educate yourself on the potential side effects of HA injections.
- Always ensure that you receive accurate dosages as prescribed by your healthcare provider.
- Keep all follow-up appointments to monitor your progress and address any concerns.
- Obtain hyaluronic acid products from reputable sources to ensure quality and safety.
For further assistance and guidance on hyaluronic acid treatments, feel free to reach out to our sales representatives who are knowledgeable and ready to help.
Ensuring Safe and Positive Outcomes with HA Treatments
Early detection of signs, effective management, and patient care are crucial in addressing HA side effects to achieve positive and safe results. Prioritizing preventive measures and patient education ensures the best standard of care and patient satisfaction.
Are Hyaluronic Acid Fillers Safe?
While hyaluronic acid fillers are generally safe when administered by trained professionals, there is a risk of adverse effects. Individual reactions may vary.
What Happens with Excessive Use of Hyaluronic Acid?
Overuse of hyaluronic acid may lead to complications like swelling, bruising, nodules, or vascular issues, which can be managed with appropriate interventions.
Who Should Avoid Hyaluronic Acid?
Key contraindications for hyaluronic acid use include pregnancy, breastfeeding, allergies to HA, skin infections, radiation therapy, scleroderma, and autoimmune diseases.
References
Philipp-Dormston WG, Goodman GJ, De Boulle K, et al. Global Approaches to the Prevention and Management of Delayed-onset Adverse Reactions with Hyaluronic Acid-based Fillers. Plast Reconstr Surg Glob Open. 2020;8(4):e2730. Published 2020 Apr 29. doi:10.1097/GOX.0000000000002730.
Funt DK. Treatment of Delayed-onset Inflammatory Reactions to Hyaluronic Acid Filler: An Algorithmic Approach. Plast Reconstr Surg Glob Open. 2022;10(6):e4362. Published 2022 Jun 20. doi:10.1097/GOX.0000000000004362.
Keen MA. Hyaluronic Acid in Dermatology. Skinmed. 2017;15(6):441-448. Published 2017 Dec 1.
Vasvani S, Kulkarni P, Rawtani D. Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies. Int J Biol Macromol. 2020;151:1012-1029. doi:10.1016/j.ijbiomac.2019.11.066.
Received 2015 Jul 21; Accepted 2015 Aug 31; Issue date 2016.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Methods
Serum samples were collected from 50 healthy individuals and 150 patients with liver diseases. These patients were diagnosed with alcoholic cirrhosis (n=50), non-alcoholic cirrhosis (n=50), and toxic hepatitis (n=50). The severity of liver cirrhosis in patients was determined using the Child–Pugh score, with 50 patients classified as class A, 50 as class B, and 50 as class C. Hyaluronic acid concentrations in serum samples were measured using immunochemical methods, specifically enzyme-linked immunosorbent assay (ELISA). Non-patented markers of liver fibrosis, such as APRI, GAPRI, HAPRI, FIB-4, and Forn’s index, were calculated using established formulas.
Results
The study found that serum hyaluronic acid levels were significantly elevated in all patient groups compared to healthy controls. Alcoholic cirrhosis patients had the highest levels of hyaluronic acid, followed by non-alcoholic cirrhosis and toxic hepatitis patients. Additionally, hyaluronic acid levels correlated positively with the severity of liver cirrhosis, with class C patients having the highest levels. Non-patented markers of liver fibrosis also showed significant differences between patient groups, with higher values observed in cirrhosis patients compared to healthy controls.
Discussion
The results of this study suggest that serum hyaluronic acid levels can serve as a useful noninvasive marker for liver damage and fibrosis. The correlation between hyaluronic acid levels and the severity of liver cirrhosis further supports its potential clinical utility. Combining hyaluronic acid measurements with other non-patented markers of liver fibrosis could enhance the accuracy of diagnosing and monitoring liver diseases. Further research is needed to validate these findings and explore the clinical implications of using hyaluronic acid as a biomarker in liver disease management.
The Role of Hyaluronic Acid in Liver Fibrosis
Research Methodology
The study included patients with alcoholic cirrhosis, non-alcoholic cirrhosis, and toxic hepatitis, categorized based on the severity of liver cirrhosis. Serum samples were collected and analyzed for various markers, with the severity of liver cirrhosis determined using the Child–Pugh score. Informed consent was obtained from all participants, and the study was approved by the Bioethical Committee.
Laboratory Analysis
Blood samples were collected from patients and controls for laboratory analysis, with hyaluronic acid levels measured using immunochemical techniques. Various other markers were also analyzed using specific formulas.
Calculation of Non-Patented Indicators
APRI, GAPRI, HAPRI, Fib-4, and Forn’s index were calculated using specific formulas based on laboratory values.
Results and Findings
The study revealed significant differences in serum hyaluronic acid levels and non-patented markers between patients with liver diseases and controls. Serum hyaluronic acid levels were elevated in all liver disease groups compared to controls, with alcoholic cirrhosis showing the highest levels. There were strong correlations between the severity of liver damage and serum hyaluronic acid levels.
Data Analysis
Results of laboratory tests in controls and patients with liver diseases according to the Child–Pugh score are presented in Table 1.
| Category | HA (ng/L) | APRI | GAPRI | HAPRI | Forn’s index | FIB-4 |
|---|
Data are presented as mean ± standard deviation
AC – Alcoholic Cirrhosis, NAC – Non-alcoholic Cirrhosis, HT – Toxic Hepatitis
Significant discrepancies were observed when comparing (ANOVA rank Kruskal-Wallis): a AC; b NAC; c HT; A Child-Pugh A; B Child-Pugh B; C Child-Pugh C
Table 2 demonstrates the diagnostic value of hyaluronic acid, APRI, GAPRI, HAPRI, FIB-4, and Forn’s index in liver diseases. Hyaluronic acid and GAPRI exhibited a high sensitivity (98.2%) in both identifying and ruling out alcoholic cirrhosis. Forn’s index and GAPRI accurately pinpointed all cases of non-alcoholic cirrhosis with a sensitivity of 100%. Forn’s index, APRI, FIB-4, and HAPRI displayed 100% specificity in excluding cases of non-alcoholic cirrhosis. GAPRI showed the highest sensitivity and positive predictive value in recognizing cases of toxic hepatitis. GAPRI, APRI, HA, and HAPRI correctly identified patients without toxic hepatitis with a specificity of 100%.
Table 2.
Evaluation of hyaluronic acid, APRI, GAPRI, HAPRI, FIB-4, and Forn’s index in diagnosing liver diseases
| Liver condition | Threshold (from ROC analysis) | Sensitivity Rate (%) | Specificity Rate (%) | Accuracy Rate (%) | Positive Predictive Value (%) | Negative Predictive Value (%) | Area Under Curve ± Standard Error |
|---|
| AC | 0.55 nanograms per milliliter | 98.2% | 100.0% | 98.7% | 100.0% | 95.2% | 0.996 ± 0.005 |
| N-Acetylcycteine | 0.72 nanograms per milliliter | 93.3 | 95.0 | 96.0 | 100.0 | 90.9 | 0.988 ± 0.011 |
| AC | 0.27 |
| 92.7 | 85.0 |
| 0.907 | 94.4 |
| 81.0 | 0.936 ± 0.029 |
| NAC | 0.34 | 96.4 | 100.0 | 0.979 | 100.0 | 95.2 | 0.996 ± 0.005 |
| Attribute | Value | Score | Accuracy | Correlation | Confidence | Quality | Variability |
|---|---|---|---|---|---|---|---|
| HT | 0.43 | 81.00 | 100.0 | 0.902 | 100.0 | 83.3 | 0.948 ± 0.032 |
| AC | 29.83 |
| 98.2 | 100.0 |
| 0.987 | 100.0 |
| 95.2 | 0.998 ± 0.002 |
| NAC | 17.722 | 100.0 | 90.0 | 0.959 | 93.5 | 100.0 | 0.993 ± 0.007 |
| HT | 25.10 | 100.0 | 100.0 | 1.0 | 100.0 | 100.0 | 1.0 ± 0.0 |
| AC | 6453.49 | 96.5 | 100.0 | 0.974 | 100.0 | 90.9 | 0.993 ± 0.007 |
| NAC | 8148.15 | 93.3 | 100.0 | 0.960 | 100.0 | 90.9 | 0.97 ± 0.012 |
The NAC value is measured at 8148.15, with a percentage of 93.3 and a rating of 100.0. The consistency ratio is 0.960, achieving a high level of 100.0. The consistency of judgments is at 90.9% with a consistency index of 0.97 ± 0.012.
| HT | 6126.13 | 77.3 | 100.0 | 0.881 | 100.0 | 80.0 | 0.875 ± 0.064 |
| AC | 1.51 | 94.4 | 100.0 | 0.959 | 100.0 | 87.0 | 0.975 ± 0.019 |
| NAC |
| 1.66 |
| 96.3 |
| 100.0 |
| 0.979 |
| 100.0 |
| 95.2 |
| 0.993 ± 0.009 |
| HT | 1.37 | 81.0 | 95.0 | 0.878 | 94.4 | 82.6 | 0.933 ± 0.039 |
| AC | 4.60 | 94.5 | 100.0 | 0.960 | 100.0 | 87.0 | 0.967 ± 0.022 |
| NAC | 4.44 | 100.0 | 100.0 | 1.0 | 100.0 | 100.0 | 1.0 ± 0.0 |
| Parameters | HT | 3.21 | 90.5 | 95.0 | 0.927 | 95.0 | 90.5 | 0.955 ± 0.033 |
|---|
AC alcoholic cirrhosis, NAC non-alcoholic cirrhosis, HT toxic hepatitis, ACC diagnostic accuracy, PPV positive predictive value, NPV negative predictive value, AUC area under ROC curve, SE standard error
GAPRI demonstrates the highest accuracy in detecting liver diseases (mean ± SE; 0.997 ± 0.022). Other indicators like Forn’s index, FIB-4, APRI, HA, and HAPRI also exhibit strong diagnostic performance with AUC values ranging from 0.946 to 0.997, indicating excellent diagnostic capability.
Discussion
While biopsy is a standard method for diagnosing liver diseases, serum markers can serve as valuable alternatives when biopsy carries risk or is not immediately available. Our study focused on hyaluronic acid as an indicator of fibrosis.
Elevated hyaluronic acid levels in liver damage occur due to increased fibrogenesis and fibrolysis. Variations in HA levels are observed across different types of cirrhosis and toxic hepatitis. Inflammation and non-alcoholic cirrhosis display distinct HA growth patterns compared to alcoholic cirrhosis. Activation of HSC leads to an increase in ECM and HA in liver damage cases. Some individuals with inflammation and fibrosis face a high risk of developing cirrhosis or cancer.
Alcoholic cirrhosis is characterized by elevated HA levels attributed to excessive ECM production and clearance issues. HA concentrations correspond to the severity of Child–Pugh scores, indicating the extent of liver damage.
HA serves as a sensitive marker for liver diseases, particularly performing well in cases of alcoholic cirrhosis. A combination of markers can enhance the assessment of liver damage.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
The human study procedures adhered to ethical standards outlined in the 1964 Helsinki Declaration.
References
- References for further reading:
- Shiha G, et al. Hepatol Int. 2009;3:323–333. doi: 10.1007/s12072-008-9114-x.
- Gressner AM, et al. Arab J Gastroenterol. 2010;10:S12–S16.
- Rostami S, et al. Hepat Mon. 2013;13:1–9. doi: 10.5812/hepatmon.13787.
- Guechot J, et al. J Hepatol. 1995;22:22–26. doi: 10.1016/0168-8278(95)80255-x.
- Rossi E, et al. Clin Biochem Rev. 2007;28:3–10.
- McHutchison JG, et al. J Gastroenterol Hepatol. 2000;15:945–951. doi: 10.1046/j.1440-1746.2000.02233.x.
- Halfon P, et al. Comp Hepatol. 2005;4:6. doi: 10.1186/1476-5926-4-6.
- Afdhal NH, Nunes D. Am J Gastroenterol. 2004;99:1160–1174. doi: 10.1111/j.1572-0241.2004.30110.x.
- Arain SA, et al. Saudi Med J. 2011;32:1241–1245.
- Rockey DC, Montgomery B. Hepatology. 2006;43:S113–S120.
- Ponomarenko Y, et al. Alcohol Alcohol. 2002;37:252–255. doi: 10.1093/alcalc/37.3.252.
- Deaciuc IV, Spitzer JJ, Shellito JE, D’Souza NB. Acute alcohol administration to mice induces hepatic sinusoidal endothelial cell dysfunction. Int Hepatol Commun. 1994;2:81–86. [Google Scholar]
- Deaciuc IV, McDonough KH, Bagby GJ, Spitzer JJ. Alcohol consumption in rats potentiates the deleterious effect of Gram-negative sepsis on hepatic hyaluronan uptake. Alcohol Clin Exp Res. 1993;17:1002–1008. doi: 10.1111/j.1530-0277.1993.tb05655.x. [DOI] [PubMed] [Google Scholar]
- Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis. Markers of progression with high prognostic value. J Hepatol. 1996;25:684–688. doi: 10.1016/s0168-8278(96)80239-x. [DOI] [PubMed] [Google Scholar]
- Valva P, Casciato P, Diaz Carrasco JM, et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS ONE. 2011;6:e23218. doi: 10.1371/journal.pone.0023218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis. 2005;9:667–683. doi: 10.1016/j.cld.2005.08.002. [DOI] [PubMed] [Google Scholar]
- Stickel F, Gudrun P, Schuppan D, et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol. 2003;15:945–950. doi: 10.1097/00042737-200309000-00002. [DOI] [PubMed] [Google Scholar]
- Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol, 2005;3:167–174. doi: 10.1016/s1542-3565(04)00625-1. [DOI] [PubMed] [Google Scholar]
Articles from Clinical and Experimental Medicine are provided here courtesy of Springer